Study of treatment effects after chemotherapy and surgery for lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial looks at how lung tumors respond after chemotherapy given before surgery in people with stage IIIA non-small cell lung cancer (NSCLC). It may help doctors understand which past treatments lead to better results, since it uses medical records from approved clinical cases.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have resectable stage IIIA non-small cell lung cancer (NSCLC).
- Your cancer tests showed lymph node involvement (N2) confirmed by biopsy or pathology.
- Your diagnosis happened between 2010 and June 2017.
- You received chemotherapy before surgery that included a platinum drug.
- You had surgery after the chemotherapy, meaning the tumor was removed.
- Your diagnosis included a PET/CT scan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at tissue samples from people with early-stage non-small cell lung cancer who received chemotherapy after surgery. The goal is to find genetic markers that predict how well treatment worked, which could help guide future care.
This trial tests whether adding an experimental cell therapy (PANK-003) to standard chemotherapy after surgery can help prevent lung cancer from coming back. It is for people with stage IIIA non-small cell lung cancer who have already had surgery and are about to start or have just started adjuvant chemotherapy.
This trial tests combining chemotherapy with immunotherapy before surgery for people with stage III non-small cell lung cancer that has a PD-L1 level of 1% or higher. The goal is to see if this approach can improve outcomes.
This trial tests a new combination of drugs given before surgery for stage III lung cancer. It aims to shrink the tumor to make surgery more effective and possibly improve your chances of a cure.
This trial tests whether the immunotherapy drug atezolizumab, given before and after surgery, can help treat stage III non-small cell lung cancer that has not spread to other parts of the body. It is for people who have not had any previous cancer treatment for this disease.
This trial tests whether giving a combination of an immunotherapy drug (serplulimab) and chemotherapy before any surgery can help shrink tumors in people with stage III lung cancer that can't be removed. The goal is to make the cancer easier to treat and improve outcomes.
Hear when a new Stage IIIA Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.